P. Rigano

发表

Deferiprone versus deferoxamine in sickle cell disease: results from a 5-year long-term Italian multi-center randomized clinical trial.

M. Steinberg, S. Ballas, R. Barone, 2014, Blood cells, molecules & diseases.

Effects of S-Adenosyl-L-Methionine on Hereditary Spherocytosis

A. Maggio, D. Renda, A. Calabrese, 1994 .

Long‐term use of deferiprone significantly enhances left‐ventricular ejection function in thalassemia major patients

P. Cianciulli, L. Cuccia, G. D'Ascola, 2012, American journal of hematology.

Transfusional Approach in Multi-Ethnic Sickle Cell Patients: Real-World Practice Data From a Multicenter Survey in Italy

F. Piel, L. De Franceschi, G. Graziadei, 2022, Frontiers in Medicine.

Raman spectroscopy technology to monitor the carotenoids in skin of thalassemia patients: a novel non-invasive tool relating oxidative stress with iron burden

L. Tesoriere, A. Attanzio, A. Maggio, 2014 .

Current challenges in the management of patients with sickle cell disease – A report of the Italian experience

S. Perrotta, M. Cappellini, L. De Franceschi, 2019, Orphanet Journal of Rare Diseases.

Real-life experience with hydroxyurea in sickle cell disease: A multicenter study in a cohort of patients with heterogeneous descent.

F. Piel, M. Cappellini, L. De Franceschi, 2017, Blood cells, molecules & diseases.

Long-term treatment with deferiprone enhances left ventricular ejection function when compared to deferoxamine in patients with thalassemia major.

P. Cianciulli, R. Barone, L. Cuccia, 2013, Blood cells, molecules & diseases.

Cerebrovascular events in sickle cell‐beta thalassemia treated with hydroxyurea: A single center prospective survey in adult Italians

M. Steinberg, A. Maggio, A. Pecoraro, 2013, American journal of hematology.

Treatment of hepatitis C virus infection with direct‐acting antiviral drugs is safe and effective in patients with hemoglobinopathies

M. Cappellini, L. De Franceschi, A. Piga, 2017, American journal of hematology.

Quantification of HBG mRNA in primary erythroid cultures: prediction of the response to hydroxyurea in sickle cell and beta‐thalassemia

M. Steinberg, R. Calzolari, A. Maggio, 2014, European journal of haematology.

The great heterogeneity of thalassemia molecular defects in Sicily.

R. Di Marzo, A. Giambona, P. Rigano, 1995, Human genetics.

Access to emergency departments for acute events and identification of sickle cell disease in refugees.

F. Piel, L. De Franceschi, G. Graziadei, 2019, Blood.

Development of interactive algorithm for clinical management of acute events related to sickle cell disease in emergency department

O. Olivieri, S. Perrotta, G. Finco, 2014, Orphanet Journal of Rare Diseases.

Treatment with hydroxycarbamide for intermedia thalassaemia: decrease of efficacy in some patients during long‐term follow up

A. Mancuso, A. Maggio, D. Renda, 2006, British journal of haematology.

Clinical and hematological response to hydroxyurea in a patient with Hb Lepore/beta-thalassemia.

R. Calzolari, A. Maggio, D. Renda, 1997, Hemoglobin.

Electrocardiographic abnormalities in thalassemia patients with heart failure.

A. Mancuso, P. Rigano, L. Mancuso, 2009, Cardiovascular & hematological disorders drug targets.

Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia

J. Tisdale, M. Hsieh, A. Maggio, 2018, International journal of molecular sciences.

The use of hydroxyurea in the real life of MIOT network: an observational study

A. Meloni, A. Pepe, A. Filosa, 2022, Expert opinion on drug safety.

Hepatocellular carcinoma in patients with thalassaemia syndromes: clinical characteristics and outcome in a long term single centre experience

F. Valenza, A. Maggio, D. Renda, 2010, British journal of haematology.

Effects of acarbose in patients with beta-thalassaemia major and abnormal glucose homeostasis.

V. De Sanctis, S. Campisi, P. Rigano, 2004, Pediatric endocrinology reviews : PER.

Long‐term sequential deferiprone–deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial

G. D’Amico, A. Morabito, C. Gluud, 2009, British journal of haematology.

Potential Myocardial Iron Content Evaluation by Magnetic Resonance Imaging in Thalassemia Major Patients Treated with Deferoxamine or Deferiprone During a Randomized Multicenter Prospective Clinical Study

A. Morabito, M. Galia, M. Midiri, 2003, Hemoglobin.

Morbidity and mortality of sickle cell disease patients is unaffected by splenectomy: evidence from three decades of follow-up in a high-income setting

F. Piel, M. Cappellini, L. De Franceschi, 2022, Haematologica.

A critical review of non invasive procedures for the evaluation of body iron burden in thalassemia major patients.

S. Vitabile, M. Midiri, A. Pepe, 2008, Pediatric endocrinology reviews : PER.

Hepatic sickling: an unusual cause of liver allograft dysfunction.

O. Ciccarelli, J. Lerut, A. Maggio, 1999, Transplantation.

Reliability of EMA Binding Test in the Diagnosis of Hereditary Spherocytosis in Italian Patients

S. Perrotta, L. Cuccia, A. Maggio, 2010, Acta Haematologica.

Desensitization to hydroxycarbamide following long‐term treatment of thalassaemia intermedia as observed in vivo and in primary erythroid cultures from treated patients

R. Calzolari, A. Maggio, A. Pecoraro, 2010, British journal of haematology.

Sequential Alternating Deferiprone And Deferoxamine Treatment Compared To Deferiprone Monotherapy: Main Findings And Clinical Follow-Up Of A Large Multicenter Randomized Clinical Trial In -Thalassemia Major Patients

G. D’Amico, A. Morabito, C. Gluud, 2011, Hemoglobin.

Efficacy of Rapamycin as Inducer of Hb F in Primary Erythroid Cultures from Sickle Cell Disease and β-Thalassemia Patients

R. Calzolari, A. Martorana, A. Maggio, 2015, Hemoglobin.

CLINICAL AND HEMATOLOGICAL RESPONSES TO HYDROXYUREA IN SICILIAN PATIENTS WITH Hb S/β-THALASSEMIA

G. Rodgers, A. Maggio, D. Renda, 2001 .

Nucleated red blood cells and soluble transferrin receptor in thalassemia syndromes: relationship with global and ineffective erythropoiesis

A. D. Di Palma, A. Maggio, R. di Concilio, 2009, Clinical chemistry and laboratory medicine.

Hydroxyurea prescription, availability and use for children with sickle cell disease in Italy: Results of a National Multicenter survey

S. Perrotta, L. Notarangelo, G. Forni, 2018, Pediatric blood & cancer.

Long‐term sequential deferiprone and deferasirox therapy in transfusion‐dependent thalassaemia patients: a prospective clinical trial

A. Pepe, L. Cuccia, V. Caruso, 2019, British journal of haematology.

Neridronate improves bone mineral density and reduces back pain in β‐thalassaemia patients with osteoporosis: results from a phase 2, randomized, parallel‐arm, open‐label study

S. Perrotta, M. Cappellini, M. Baldini, 2012, British Journal of Haematology.

Selecting β-thalassemia Patients for Gene Therapy: A Decision-making Algorithm

A. Iolascon, L. De Franceschi, G. Graziadei, 2021, HemaSphere.

Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies.

P. Cianciulli, L. Cuccia, V. Caruso, 2009, Blood cells, molecules & diseases.

Nonsense-mediated decay mechanism is a possible modifying factor of clinical outcome in nonsense cd39 beta thalassemia genotype

M. Attanasio, A. Maggio, A. Giambona, 2012 .

Hepatocellular carcinoma on cirrhosis‐free liver in a HCV‐infected thalassemic

A. Mancuso, A. Maggio, D. Renda, 2005, American journal of hematology.

Effects of acarbose in beta-thalassaemia major patients with normal glucose tolerance and hyperinsulinism.

V. De Sanctis, S. Campisi, P. Rigano, 2004, Pediatric endocrinology reviews : PER.

Selecting ß-Thalassemia Patients for Gene Therapy: A Decision-Making Algorithm

A. Iolascon, M. Cappellini, G. Graziadei, 2019, Blood.

Serial echocardiographic left ventricular ejection fraction measurements: a tool for detecting thalassemia major patients at risk of cardiac death.

N. Chattipakorn, A. Phrommintikul, P. Cianciulli, 2013, Blood cells, molecules & diseases.

Age at diagnosis as an indicator of eligibility for BRCA1 DNA testing in familial breast cancer

H. Kazazian, F. Chehab, F. Trapani, 2004, Human Genetics.

Treatment with hydroxyurea and iron chelation therapy in patients with hemoglobinopathies

G. D’Amico, A. Maggio, P. Rigano, 2005, European journal of haematology.

Acute hemolytic transfusion reaction by anti‐P1 antibody in pregnancy

K. Ishizawa, A. Mancuso, H. Harigae, 2005, American journal of hematology.

PF737 SURVIVAL RATES AND CAUSES OF DEATH IN ELDERLY PATIENTS WITH SICKLE CELL DISEASE

G. Graziadei, B. Gianesin, V. Pinto, 2019, HemaSphere.

Reliability of EMA Binding Test in the Diagnosis of Hereditary Spherocytosis in Italian Patients

S. Perrotta, L. Cuccia, A. Maggio, 2010, Acta Haematologica.